|Bid||36.85 x 800|
|Ask||36.90 x 900|
|Day's Range||36.71 - 38.00|
|52 Week Range||16.10 - 38.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.40|
Novocure (NVCR) has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure’s board in July 2018. “We are extremely pleased to welcome Jeri to our board of directors,” said Bill Doyle, Novocure’s Executive Chairman.
Novocure (NVCR) announced today that the results of its INNOVATE phase 2 pilot trial have been published in Gynecologic Oncology. The INNOVATE trial was a prospective, single-arm study testing the feasibility, safety and preliminary efficacy of Tumor Treating Fields combined with weekly paclitaxel in recurrent ovarian cancer. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.
NovoCure (NVCR) released its second-quarter results on July 26. In the second quarter, NovoCure continued to see steady growth in patient prescriptions for new glioblastoma diagnosis. NovoCure reported a net loss of $15.51 million in the second quarter—compared to a net loss of $21.17 million in the second quarter of 2017.
Quarterly net revenues of $61.5 million, representing 60 percent growth versus the second quarter 2017 and 18 percent growth versus the first quarter 2018
NovoCure (NVCR) is expected to incur SG&A (selling, general, and administrative) expenses of $35.4 million in the second quarter, compared with $31.38 million in the second quarter of 2017, an increase of 12.8%. NovoCure’s R&D (research and development) expenses are expected to increase 47.06% from $9.37 million in the second quarter of 2017 to $13.78 million in the second quarter. NovoCure’s total operating expenses are expected to increase 18.1% from $40.75 million in the second quarter of 2017 to $48.13 million in the second quarter.
NovoCure (NVCR) is expected to report its second-quarter earnings on July 26. In this series, we’ll look at the company’s top-line, operational, and bottom-line performance expected by analysts for the second quarter. We’ll also look at analysts’ recommendations and the performance of NovoCure stock so far this year.
The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference
Batting first and playing RF, we have GDS Holdings Ltd. (NASDAQ: GDS). GDS is one of the leading carrier-neutral data center solutions providers in China, and the growing demand for its services has led to impressive growth.
The IEEE Engineering in Medicine and Biology Society’s 40th International Conference is the first conference in which a scientific track will be devoted to Tumor Treating Fields, i
On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Medical Appliances & Equipment equities this morning: Nevro Corp. (NYSE: NVRO), NovoCure Ltd (NASDAQ: NVCR), NuVasive Inc. (NASDAQ: NUVA), and Stryker Corp. (NYSE: SYK).
To receive further updates on this Novocure Ltd (NASDAQ:NVCR) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.
Novocure (NVCR) announced today that Pritesh Shah has been appointed as Novocure’s Chief Commercial Officer, reporting to Novocure’s Chief Executive Officer Asaf Danziger. In this role, Mr. Shah will be responsible for the development and execution of Novocure’s commercialization strategy worldwide, and for overseeing Novocure’s international business units.
Novocure announced today that it will report financial results for the second quarter 2018 on Thursday, July 26, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and six months ended June 30, 2018, at 8 a.m.
NovoCure Limited made a small base pattern in 2016 and started a strong rally in 2017 and moving up four-fold from its 2017 nadir. Let's review the charts and indicators of NVCR to see what the prospects look like for this company.
Jim Cramer zooms through his take on callers' favorite stocks and lists his top picks in the cybersecurity space.
NEW YORK, June 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NovoCure ...
Shares retreat after the company releases details about an upcoming phase 3 trial. Should investors be worried, or is this just market noise?
Novocure (NVCR) will present today for the first time the design of its phase 3 pivotal trial of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 in Chicago. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. INNOVATE-3, a prospective, open-label study, will include 540 patients with recurrent, platinum-resistant ovarian cancer.
Dr. David T. Hung and Sherilyn D. McCoy, both experienced executive leaders, were elected to Novocure’s board at the annual general meeting of shareholders on May 31. Gert Lennart Perlhagen is retiring from the board after 15 years of service. “We are extremely pleased to welcome David and Sheri to our board,” said Bill Doyle, Novocure’s Executive Chairman.
WallStEquities.com has selected the following Medical Appliances and Equipment stocks for review this morning: Lantheus Holdings Inc. (NASDAQ: LNTH), Nevro Corp. (NYSE: NVRO), NovoCure Ltd (NASDAQ: NVCR), and NuVasive Inc. (NASDAQ: NUVA). North Billerica, Massachusetts headquartered Lantheus Holdings Inc.'s shares gained slightly by 0.35%, closing Wednesday's trading session at $14.20.